DNA icon

Syndromic Intellectual Disability/Autism Spectrum Disorder via the DYRK1A Gene

Summary and Pricing

Test Method

Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture Probes
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
DYRK1A 81479 81479,81479 $990
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
8137DYRK1A81479 81479,81479 $990 Order Options and Pricing

Pricing Comments

Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.

Turnaround Time

3 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.


Genetic Counselors


  • Greg Fischer, PhD

Clinical Features and Genetics

Clinical Features

Autism Spectrum Disorders (ASD) encompass several neurodevelopmental disorders characterized by varying degrees of social impairment, communication ability, and propensity for restricted interests and repetitive behavior(s) which usually present by age 3. Diagnosis is based on the degree and severity of symptoms and behaviors (Diagnostic and Statistical Manual of Mental Disorders (DSM-5); Levy et al., 2009. PubMed ID: 19819542; McPartland et al., 2016.). Comorbidities occur in more than 70% of cases and include intellectual disability (ID), epilepsy, language deficits, and gastrointestinal problems (Sztainberg & Zoghbi 2016. PubMed ID: 27786181). ID specifically refers to significant impairment of cognitive and adaptive development (intelligence quotient, IQ<70) due to abnormalities of brain structure and/or function (American Association of Intellectual and Developmental Disabilities, AAIDD). ID is not a single entity, but rather a general symptom of neurologic dysfunction that is diagnosed before age 18 in ~1-3% of the population (Kaufman et al., 2010. PubMed ID: 21124998; Vissers et al., 2016. PubMed ID: 26503795).

Variants impacting the DYRK1A gene have been implicated in a syndromic form of ID and ASD characterized by moderate to severe ID (100%), absent or delayed speech (100%), primary or acquired microcephaly (100%), feeding difficulties (~93%), and seizures (87.5%). Additional clinical features such as a thin upper lip (~87%), deep-set eyes with full/hooded upper lids (86%), stereotypies (80%), hyperopia/myopia (~78%), micrognathia (~71%), and uncoordinated movement (75%) allow for distinction from other disorders that share the same cardinal features (Bronicki et al., 2015. PubMed ID: 25920557). Short stature, skeletal issues, gait abnormalities, constipation, gastroesophageal reflux, pyloric stenosis, tapered fingers, and brain abnormalities including hypoplastic pituitary stalk and corpus callosum, white matter hypomyelination, frontal lobe and cortical atrophy, gliosis, and thin optic chiasm have also been reported (Ji et al., 2015. PubMed ID: 25944381).


DYRK1A (dual-specificity tyrosine-phosphorylation-regulated kinase, DYRK) is a DYRK kinase protein that is 763 amino acids in length. All DYRK kinase proteins contain a catalytic kinase domain (residues 159-479 in DYRK1A) and a DYRK homology box. DYRK1A specifically includes two nuclear localization signals, a PEST domain, a speckle-targeting signal, and histidine, serine/threonine repeat domains. DYRK1A is located on chromosome 21 within the Down’s syndrome critical region (DSCR) that, when triplicated, results in Down’s syndrome features (Evers et al., 2017. PubMed ID: 28053047). It is widely expressed in the developing nervous system, and dosage is strictly regulated as both overexpression and haploinsufficiency adversely impact neurite length and axonal outgrowth (Dang et al., 2017. PubMed ID: 28167836).

DYRK1A pathogenic variants are almost exclusively de novo and result in syndromic ID and ASD phenotypes in an autosomal dominant manner. Comparisons of variants identified in affected individuals with apparently benign DYRK1A variants identified in population databases have revealed that pathogenic variants tend to occur before the C-terminal end of the kinase domain (residue 479), whereas variants identified in population databases occur before the first N-terminal nuclear localization signal or after the kinase domain. Genotype-phenotype correlations have been suggested as more severe phenotypes are associated with variants in close proximity to the catalytic loop or substrate binding site of the kinase domain (Evers et al., 2017. PubMed ID: 28053047).

Clinical Sensitivity - Sequencing with CNV PG-Select

Currently, the contribution of de novo and inherited factors to Autism Spectrum Disorders (ASD) risk is estimated to be approximately 50-60% (Krumm et al., 2015. PubMed ID: 25961944) and 25-50% for intellectual disability (ID), with the percentage increasing proportionately with phenotypic severity (McLaren & Bryson 1987. PubMed ID: 3322329). DYRK1A is classified in the Simons Foundation Autism Research Initiative (SFARI) Database as a ‘high confidence, syndromic’ gene candidate regarding ASD risk (https://gene.sfari.org/database/human-gene/DYRK1A). However, more than 700 genes total have been associated with ASD features (Bourgeron 2016. PubMed ID: 27289453). A recent report has suggested that de novo loss of function variants within DYRK1A account for 0.5% of syndromic intellectual disability cases (Evers et al., 2017. PubMed ID: 28053047) with well over 100 de novo heterozygous nonsense, frameshift, splice-altering, and chromosomal rearrangements being described in the literature (Dang et al., 2017. PubMed ID: 28167836).

Overall, de novo copy number variants (CNVs) are estimated to account for approximately 6% of ASD risk (Lim et al., 2013. PubMed ID: 23352160). The contribution of DYRK1A CNVs specifically is unclear; however, DYRK1A resides in the Down syndrome critical region (DSCR) in which numerous deletions and duplications have been reported. Most microdeletions in this region encompass multiple genes, but all include the entire DYRK1A gene. Chromosomal translocations and deletions encompassing only the 5’UTR region of DYRK1A have also been reported in affected individuals (Ji et al., 2015. PubMed ID: 25944381).

Testing Strategy

This test provides full coverage of all coding exons of the DYRK1A gene, plus ~10 bases of flanking noncoding DNA. We define full coverage as >20X NGS reads or Sanger sequencing.

Indications for Test

Individuals presenting with the cardinal features of DYRK1A-associated intellectual disability (ID, microcephaly, feeding difficulties, absent or delayed speech, and seizures) with dysmorphic facial features, ASD, visual impairment, and MRI abnormalities are good candidates for this test. Of note, a large majority of reported pathogenic variants in which parental DNA was tested confirmed they arose de novo, therefore testing with parental samples is highly recommended (Bronicki et al., 2015. PubMed ID: 25920557).


Official Gene Symbol OMIM ID
DYRK1A 600855
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT


Name Inheritance OMIM ID
Mental Retardation, Autosomal Dominant 7 AD 614104


  • Bourgeron., 2016. PubMed ID: 27289453
  • Bronicki et al., 2015. PubMed ID: 25920557
  • Dang et al., 2017. PubMed ID: 28167836
  • Evers et al., 2017. PubMed ID: 28053047
  • Ji et al., 2015. PubMed ID: 25944381
  • Kaufman et al., 2010. PubMed ID: 21124998
  • Krumm et al., 2015. PubMed ID: 25961944
  • Levy et al., 2009. PubMed ID: 19819542
  • Lim et al., 2013. PubMed ID: 23352160
  • McLaren, Bryson, 1987. PubMed ID: 3322329
  • McPartland et al., 2016. Encyclopedia of Mental Health. 2: 124-130.
  • Sztainberg & Zoghbi 2016. PubMed ID: 27786181
  • Vissers et al., 2016. PubMed ID: 26503795


Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page

If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.

Specimen Types

Specimen Requirements and Shipping Details

loading Loading... ×


An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)

1) Select Test Type

2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
Copy Text to Clipboard